Deep Medicine Acquisition Corp.
Status: Deal Closed
U=S+R
R=S/10
IPO Proceeds, $M | $126.50M |
---|---|
IPO Date | Oct 27, 2021 |
CEO | Humphrey P. Polanen |
Left Lead | I-Bankers Securities |
IPO Cash in Trust | 101.0% |
SPAC Tenor | 12 + 3 + 6 + 6 + 6 |
IPO Sector | Healthcare |
IPO Geography | Global |
Target Company | TruGolf |
Deal Announced | Jul 13, 2022 |
Deal Size, $M | $125.00M |
Deal Sector | Consumer |
Deal Geography | US/Canada |
SEC Filings | www.sec.gov |
Approval Vote | Jan 19, 2024 |
Amendment Vote | Jan 26, 2024 |
Closing Date | Jan 31, 2024 |
Formerly DMAQ
TRUG
Price | $0.48 |
---|---|
Last closing price | $0.48 |
Volume, today | 92,453 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Deep Medicine Acquisition Corp.:
- Structure and cap table
- 9 directors & officers
- 42 filings and events
- 3 underwriters
- 2 legal advisors
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Humphrey P. Polanen | 72 | CEO and Chairman |
Weixuan Luo | 48 | CFO |
Ronald M. Razmi, MD | 51 | Director |
Tina Spires | 44 | Director |
HongLiang Ren | 41 | Director |
Bryant E. Fong | 48 | Director |
Marc A. Hamer | 48 | Director |
Wanlei Miao | 37 | Director |
John Chiang | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
I-Bankers Securities | BR | 8,400,000 | units |
Dawson James | 1,600,000 | ||
Ingalls & Snyder | 1,000,000 | ||
11,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
BCMA | 3.50 | % |
Sign in to view more advisor data.
Deal
Sign in to view merger details and deal financials.